Teriparatide CAS:52232-67-4

Teriparatide is indicated for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. Its therapeutic effects result from the stimulation of bone formation and restoration of bone architecture, leading to increased bone mineral density and improved skeletal integrity. Teriparatide therapy has been shown to reduce the risk of vertebral and non-vertebral fractures, including hip fractures, in patients with severe osteoporosis. In clinical practice, teriparatide is administered as a once-daily subcutaneous injection, offering a convenient and effective treatment option for patients. Its favorable safety profile and demonstrated efficacy in reducing fracture risk make it a preferred choice for individuals with severe osteoporosis who are at increased risk of fractures despite other treatments. Moreover, teriparatide may have additional benefits beyond fracture prevention, such as improving bone strength and quality. Studies have suggested that teriparatide therapy may lead to increased bone turnover and enhanced bone microarchitecture, further contributing to skeletal health and reducing fracture risk in osteoporotic patients. Overall, teriparatide represents a cornerstone in the management of severe osteoporosis, offering a targeted approach to stimulate bone formation and reduce fracture risk. Its daily subcutaneous administration, coupled with its proven efficacy in improving bone health, makes it a valuable treatment option for individuals at high risk of osteoporotic fractures.